WALGREEN CO. FORM 8-K (Unscheduled Material Events) Filed 6/5/2006 For Period Ending 6/5/2006

Size: px
Start display at page:

Download "WALGREEN CO. FORM 8-K (Unscheduled Material Events) Filed 6/5/2006 For Period Ending 6/5/2006"

Transcription

1 WALGREEN CO FORM 8-K (Unscheduled Material Events) Filed 6/5/2006 For Period Ending 6/5/2006 Address 200 WILMOT RD DEERFIELD, Illinois Telephone CIK Industry Retail (Drugs) Sector Services Fiscal Year 08/31

2 SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2006 WALGREEN CO. (Exact name of registrant as specified in its charter) Illinois (State or other (Commission File (IRS Employer jurisdiction of Number) Identification incorporation) Number) 200 Wilmot Road, Deerfield, Illinois (Address of principal executive offices) (Zip Code) Registrant s telephone number, including area code: (847) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR ) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR e-4(c))

3

4 Item OTHER EVENTS. On June 5, 2006, Walgreen Co. issued a press release announcing that the Delaware-based Happy Harry s pharmacy chain has agreed to a merger with Walgreen Co. The information contained in this press release, which is filed as Exhibit 99.1 to this Form 8- K, is incorporated herein by reference. Item FINANCIAL STATEMENTS AND EXHIBITS. (d) The following exhibit is being filed as part of this Form 8-K: Exhibit Number Description Exhibit 99.1 Press Release issued by Walgreen Co., dated June 5, 2006

5 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WALGREEN CO. Date: June 5, 2006 By: /s/ William M. Rudolphsen Senior Vice President and Chief Financial Officer (Principal Financial Officer)

6 Walgreen Co. Corporate Communications 200 Wilmot Road Deerfield, Ill (847) Contact: Michael Polzin of Walgreens, (847) Alan Levin of Happy Harry's, (302) June 5, 2006 NASDAQ: WAG FOR IMMEDIATE RELEASE INTERNET: NYSE, HAPPY HARRY S PHARMACY CHAIN TO MERGE WITH WALGREENS DEERFIELD, Ill. - Walgreen Co. (NYSE, NASDAQ: WAG) Chairman and CEO Dave Bernauer and Happy Harry s Inc. Chairman and CEO Alan Levin today announced that Delaware-based Happy Harry s pharmacy chain has agreed to a merger with Walgreens. Financial terms of the agreement weren t disclosed. The transaction includes all 76 Happy Harry s stores in Delaware, Pennsylvania, Maryland and New Jersey, and the corporate office and distribution center in Newark, Del. "Happy Harry s is one of the strongest regional chains in the drugstore industry with a great following in a market where we have little presence," said Bernauer. "Its brand reputation and market share are a great base from which to build our presence there. These stores are performing well and will benefit us right from the start." Levin, whose father Harry Levin founded Happy Harry s in 1962, said, "My father would be proud of the accomplishments we ve made and very pleased with today s announcement. He always believed, as do I, in putting our customers and employees first, and so does Walgreens." The merger is subject to regulatory approval and is expected to close this summer. Afterward, Levin will continue working with Walgreens. "I m excited by the opportunities this merger presents for both the employees of Happy Harry s and our customers," said Levin. Organic growth has been and will continue to be Walgreens primary growth vehicle. Over the last 10 years, Walgreens has opened more than 3,800 new locations while acquiring and operating fewer than 30 retail drugstores. "Retail acquisitions are rare for us, but Happy Harry s presented a unique opportunity and is a solid strategic fit," said Bernauer. This is Walgreens largest acquisition since 1986, when it purchased the 66-store Medi Mart chain in the Northeast. (more)

7 Walgreens vice president of store operation s Frank Grilli, who will lead the integration of the new stores, said, "Happy Harry s customers will see the same service levels and same employees in the stores. Their knowledge of their customers and markets will be invaluable "We plan to keep the name and look of the stores the same, while over time evaluating the benefits of incorporating or substituting the Walgreens name," added Grilli. "The only exceptions to this are the eight stores in Pennsylvania, where the decision has already been made to convert the stores to the Walgreens name because of our stronger branding there." Walgreens also recognizes the relationships Happy Harry s has built with many Delaware community organizations. "Our companies have similar histories," said Bernauer. "They re family-founded with a family name and family involvement. Being part of the community is another common value we share, and we look forward to Alan continuing to direct that involvement in the region." Walgreens expects to continue accepting all prescription insurance plans currently taken by Happy Harry s after the transaction closes. Once Happy Harry s pharmacy patients are part of Walgreens Intercom Plus pharmacy computer system, they can have their prescriptions accessed and filled at any of the more than 5,200 Walgreens nationwide. Walgreen Co. is the nation's largest drugstore chain with fiscal 2005 sales of $42.2 billion. The company operates 5,251 stores in 45 states and Puerto Rico. Walgreens also provides additional services to pharmacy patients and prescription drug and medical plans through Walgreens Health Services, its managed care division, which includes Walgreens Health Initiatives Inc. (a pharmacy benefits manager), Walgreens Mail Service Inc., Walgreens Home Care Inc. and Walgreens Specialty Pharmacy. # # # # #

DCP MIDSTREAM, LP FORM 8-K. (Current report filing) Filed 04/13/12 for the Period Ending 04/09/12

DCP MIDSTREAM, LP FORM 8-K. (Current report filing) Filed 04/13/12 for the Period Ending 04/09/12 DCP MIDSTREAM, LP FORM 8-K (Current report filing) Filed 04/13/12 for the Period Ending 04/09/12 Address 370 17TH STREET SUITE 2500 DENVER, CO, 80202 Telephone 303-595-3331 CIK 0001338065 Symbol DCP SIC

More information

HILLENBRAND INDUSTRIES INC

HILLENBRAND INDUSTRIES INC HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518

More information

FORM8-K HILLENBRAND,INC.

FORM8-K HILLENBRAND,INC. UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): February1,2016

More information

FORM8-K HILLENBRAND,INC.

FORM8-K HILLENBRAND,INC. UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015

More information

WALGREENS BOOTS ALLIANCE, INC.

WALGREENS BOOTS ALLIANCE, INC. WALGREENS BOOTS ALLIANCE, INC. FORM 8-K (Current report filing) Filed 01/30/17 for the Period Ending 01/26/17 Address 108 WILMOT ROAD DEERFIELD, IL 60015 Telephone (847) 315-2500 CIK 0001618921 Symbol

More information

Inovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

Inovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

VICAL INC FORM 8-K. (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06

VICAL INC FORM 8-K. (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06 VICAL INC FORM 8-K (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06 Address 10390 PACIFIC CENTER COURT. SAN DIEGO, CA 92121-4340 Telephone 858-646-1100 CIK 0000819050 Symbol VICL SIC

More information

PIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)

PIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

Capital Senior Living Corporation

Capital Senior Living Corporation UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

ABSOLUTE NNN LEASE 19 Years Remaining 8815 Stagecoach Rd. Little Rock, AR 72210

ABSOLUTE NNN LEASE 19 Years Remaining 8815 Stagecoach Rd. Little Rock, AR 72210 ABSOLUTE NNN LEASE 19 Years Remaining 8815 Stagecoach Rd. Little Rock, AR 72210 Price- $6,330,275 Cap Rate-5.45% Absolute Net Lease with 19 Years Remaining on Initial Lease Term. Lease Guaranteed by Walgreen

More information

VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter)

VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

Oragenics, Inc. (Exact name of registrant as specified in its charter)

Oragenics, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: September 25, 2018

More information

EXCLUSIVELY LISTED INVESTMENT OFFERING

EXCLUSIVELY LISTED INVESTMENT OFFERING EXCLUSIVELY LISTED INVESTMENT OFFERING ATLANTA MSA INVESTMENT OPPORTUNITY DALLAS, GA 30132 Presented By: JASON STUART PONGSRIKUL Managing Principal x 302 CA DRE Lic. 01918332 NICK PRICE Senior Vice President

More information

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington D.C

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington D.C FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2009 Commission

More information

Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT

More information

DARA Reports Year-End 2012 Financial Results

DARA Reports Year-End 2012 Financial Results April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,

More information

RULES OF CONDUCT OF INSIDERS RESPECTING

RULES OF CONDUCT OF INSIDERS RESPECTING T RULES OF CONDUCT OF INSIDERS RESPECTING RADING O F SECURITIES OF TFI International lnc. Amended and restated July 2015 Executive Summary As an insider of TFI International Inc. ( TFI International )

More information

Walgreens Pharmacy 2551 W. Main Street Alhambra, CA $10,300,000

Walgreens Pharmacy 2551 W. Main Street Alhambra, CA $10,300,000 Walgreens Pharmacy 2551 W. Main Street Alhambra, CA 91801 $10,300,000 INVESTMENT HIGHLIGHTS Rare LA County, Walgreens Net Leased Offering Population in Excess of 265,328 Within 3 Miles Located Blocks Away

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT

More information

WALGREENS IN-23 - GRANGER, INDIANA offering memorandum. Actual Property

WALGREENS IN-23 - GRANGER, INDIANA offering memorandum. Actual Property WALGREENS offering memorandum Financial Overview Offering Summary PRICE $5,200,000 CAP RATE 6.25% NOI $325,000 PRICE PER SQUARE FOOT $358.87 RENT PER SQUARE FOOT $22.43 YEAR BUILT 2003 GROSS LEASEABLE

More information

Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation

Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation TD-1211 Achieves Primary and Secondary Endpoints SOUTH SAN FRANCISCO,

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT

More information

NET LEASE INVESTMENT OFFERING RITE AID PHARMACY

NET LEASE INVESTMENT OFFERING RITE AID PHARMACY RITE AID PHARMACY 11702 Lorain Avenue Cleveland, OH 44111 TABLE OF CONTENTS TABLE OF CONTENTS I. Executive Profile Executive Summary Investment Highlights Property Overview II. Location Overview Photographs

More information

NET LEASE INVESTMENT OFFERING WALGREENS

NET LEASE INVESTMENT OFFERING WALGREENS WALGREENS 5320 Clinton Highway Knoxville, TN 37912 TABLE OF CONTENTS TABLE OF CONTENTS I. Executive Profile Executive Summary Investment Highlights Property Overview II. Location Overview Photographs Aerials

More information

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K. Neuralstem, Inc. (Exact name of registrant as specified in Charter)

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K. Neuralstem, Inc. (Exact name of registrant as specified in Charter) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):

More information

NET LEASE PORTFOLIO INVESTMENT OPPORTUNITY

NET LEASE PORTFOLIO INVESTMENT OPPORTUNITY NET LEASE PORTFOLIO INVESTMENT OPPORTUNITY Walgreens Portfolio Three Properties Knoxville, TN Port Orchard, WA Cincinnati, OH Available on an Individual or Portfolio Basis DISCLAIMER STATEMENT DISCLAIMER

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event

More information

Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-

Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance- Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-

More information

Standards of Conduct for Transmission Providers

Standards of Conduct for Transmission Providers Standards of Conduct for Transmission Providers Posted and Effective as of December 30, 2016 Puget Sound Energy ( PSE ) is a public utility that owns, operates, and controls facilities used for the transmission

More information

Mount Prospect, Illinois

Mount Prospect, Illinois 1 Mile 3 Mile 5 Mile Population 1,189 1,659 337,66 Avg. HH Income $17, $85,16 $9,441 Landmark Walgreens Corporate HQ O Hare Airport Downtown Chicago Drive Time 1 minutes 15 minutes 35 minutes Walgreens

More information

MYOS RENS Technology CEO Joseph Mannello Issues Letter to Shareholders

MYOS RENS Technology CEO Joseph Mannello Issues Letter to Shareholders December 14, 2018 MYOS RENS Technology CEO Joseph Mannello Issues Letter to Shareholders CEDAR KNOLLS, N.J., Dec. 14, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS),

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event

More information

The Value of Walgreens

The Value of Walgreens The Value of Walgreens How Walgreens improves employer health plans through access, quality and lower costs Why millions of patients choose Walgreens And your options to move forward with Walgreens Walgreens

More information

Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K. ADVAXIS, INC. (Exact Name of Registrant as Specified in Charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K. ADVAXIS, INC. (Exact Name of Registrant as Specified in Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event

More information

Integrity Applications, Inc. (Exact Name of Registrant as Specified in Its Charter)

Integrity Applications, Inc. (Exact Name of Registrant as Specified in Its Charter) Date of Report (Date of earliest event reported): October 29, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Registrant s telephone number, including area code: 972 (8) 675-7878

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C Form 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month

More information

Teaming Agreement. Grant of Charter and License. Dues. Name and Logo. Mission Commitment. Chapter Standards Compliance.

Teaming Agreement. Grant of Charter and License. Dues. Name and Logo. Mission Commitment. Chapter Standards Compliance. Teaming Agreement Grant of Charter and License Dues Name and Logo Mission Commitment Chapter Standards Compliance Service Provision Communication Commitments and Chapter Benefits Separate Entities Termination

More information

AVEO and Astellas Report Final Overall Survival Results from TIVO-1

AVEO and Astellas Report Final Overall Survival Results from TIVO-1 AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,

More information

Shire Comments on Press Release from NPS Pharma Regarding FDA Approval of NATPARA (parathyroid hormone)

Shire Comments on Press Release from NPS Pharma Regarding FDA Approval of NATPARA (parathyroid hormone) Press Release www.shire.com Shire Comments on Press Release from NPS Pharma Regarding FDA Approval of NATPARA (parathyroid hormone) Dublin, Ireland January 23, 2015 Shire plc (LSE: SHP, NASDAQ: SHPG) notes

More information

Walgreens.com. Seeklogo.com. Walgreens.com. Walgreens.com. Walgreens

Walgreens.com. Seeklogo.com. Walgreens.com. Walgreens.com. Walgreens Walgreens.com Seeklogo.com Walgreens.com Walgreens.com Walgreens Our Vision 1 To be America's most loved pharmacy-led health, wellbeing and beauty retailer. Our Purpose To champion everyone s right to

More information

PHARMACY BENEFITS MANAGER SELECTION FAQ FOR PRODUCERS

PHARMACY BENEFITS MANAGER SELECTION FAQ FOR PRODUCERS PHARMACY BENEFITS MANAGER SELECTION FAQ FOR PRODUCERS For Producer Audience Only - Please Do Not Distribute Regence has selected Prime Therapeutics as the Pharmacy benefits manager for its health plans.

More information

RITE AID. Investment Property Offering $2,168, West Shore Road, Warwick, RI Offering Highlights

RITE AID. Investment Property Offering $2,168, West Shore Road, Warwick, RI Offering Highlights Investment Property Offering $2,168,774 RITE AID 2595 West Shore Road, Warwick, RI 02889 Presented By: Kase Abusharkh 252 Abigail Circle Danville, CA 94506 (925)348-1844 kase@svn.com Offering Highlights

More information

Tamsulosin Hydrochloride 0.4 mg Capsule

Tamsulosin Hydrochloride 0.4 mg Capsule Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule

More information

AstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15.

AstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15. [NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS

More information

RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit

RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit December 11 12, 2018 Workshops, December 10, 2018 The Revere Hotel 200 Stuart St., Boston,

More information

Walmart drug prices generic

Walmart drug prices generic Walmart drug prices generic The Borg System is 100 % Walmart drug prices generic Compare prescription drug prices and find coupons at more than 60,000 US pharmacies. Save up to 80% instantly! Compare prescription

More information

PIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)

PIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Your contact. Merck and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody

Your contact. Merck and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody Your contact Merck Media: Gangolf Schrimpf +49 6151 72 9591 Investor Relations: +49 6151 72 3321 News Release Pfizer Media: Sally Beatty +1 212 733 6566 Investor Relations: Ryan Crowe +1 212 733 8160 May

More information

ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL

ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL PROVINCE OF BRITISH COLUMBIA ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL Order in Council No. 542, Approved and Ordered October 5, 2018 Executive Council Chambers, Victoria On the recommendation of the

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

Investment in MGC Pharmaceuticals

Investment in MGC Pharmaceuticals Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information

More information

EXCLUSIVELY LISTED INVESTMENT OFFERING

EXCLUSIVELY LISTED INVESTMENT OFFERING EXCLUSIVELY LISTED INVESTMENT OFFERING WALGREENS INVESTMENT OPPORTUNITY 4600 86TH STREET Exclusively Listed By JASON STUART PONGSRIKUL MANAGING PRINCIPAL Pharma Property Group 5328 Banks Street, Suite

More information

DRONE FOOTAGE AVAILABLE

DRONE FOOTAGE AVAILABLE RITE AID 535 Portland Avenue Rochester, NY Rite Aid #03597 Rochester Click here to view drone video footage of the property! DRONE FOOTAGE AVAILABLE Click here to view drone photos of the property! TABLE

More information

EXCLUSIVELY LISTED INVESTMENT OFFERING

EXCLUSIVELY LISTED INVESTMENT OFFERING EXCLUSIVELY LISTED INVESTMENT OFFERING ILLINOIS INVESTMENT OPPORTUNITY RESIDENTIAL AREAS SUBJECT PROPERTY RESIDENTIAL AREAS Presented By: JASON STUART PONGSRIKUL Direct: 619.297.0055 x 302 jp@pharmapropertygroup.com

More information

January 30, 2018 Dow Wilson President and Chief Executive Officer

January 30, 2018 Dow Wilson President and Chief Executive Officer Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking

More information

CytoDyn Inc. (Exact name of registrant as specified in its charter)

CytoDyn Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement

Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement For immediate release April 28, 2005 Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement Dainippon Pharmaceutical Co., Ltd. Sumitomo Pharmaceuticals Co., Ltd. Dainippon Pharmaceutical

More information

6.00% CAP Rate $5,600,000. DeerfieldPartners. John Giordani Art Griffith (415) Actual Store

6.00% CAP Rate $5,600,000. DeerfieldPartners. John Giordani Art Griffith (415) Actual Store Actual Store Low Price & Great Value $5,6, 6.% CAP Rate Open & paying rent--available for immediate sale Lower price point and great value Offered free & clear; loans available today with as little as

More information

Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801)

Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801) News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Receives FDA Approval of BRACAnalysis CDx as Companion

More information

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)

More information

Supplier Code of Business Conduct

Supplier Code of Business Conduct Supplier Code of Business Conduct We act with integrity, honesty and respect. Sempra Energy Values We are an ethical, respectful, high performing, forward looking, responsible partner. Our values define

More information

ARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C

ARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C ARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C OCTOBER 11, 2017 NASDAQ: ARDX FORWARD-LOOKING STATEMENTS To the extent that statements contained in this presentation are not descriptions

More information

WASHINGTON,D.C FORM8-K. CurrentReport PursuanttoSection13or15(d)ofthe

WASHINGTON,D.C FORM8-K. CurrentReport PursuanttoSection13or15(d)ofthe UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION WASHINGTON,D.C.20549 FORM8-K CurrentReport PursuanttoSection13or15(d)ofthe SecuritiesExchangeActof1934 April3,2017 DateofReport(DateofEarliestEventReported)

More information

Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva )

Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva ) Press release 7 September 2017 Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva ) Achieved significant and clinically

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION JUNE 2016 OTCQB:CANN ABOUT General Cannabis Corporation (GCC) is the all-in-one resource for the highest quality service providers available to the regulated Cannabis Industry. We

More information

BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease

BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease Press release BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in

More information

Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome

Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008

More information

City of Carson 701 E. Carson St., Carson, CA Telephone: (310) ; ci.carson.ca.us

City of Carson 701 E. Carson St., Carson, CA Telephone: (310) ; ci.carson.ca.us OFFICE USE ONLY Case No. City of Carson 701 E. Carson St., Carson, CA 90745 Telephone: (310) 830-7600; ci.carson.ca.us Application Submittal Date Fee Accepted By SUPPLEMENTAL APPLICATION FOR COMMERCIAL

More information

WALGREENS 2310 WEST PATAPSCO AVENUE, BALTIMORE, MD BRANDON MICHAELS GROUP

WALGREENS 2310 WEST PATAPSCO AVENUE, BALTIMORE, MD BRANDON MICHAELS GROUP WALGREENS 2310 WEST PATAPSCO AVENUE, BALTIMORE, MD 21230 BRANDON MICHAELS GROUP INVESTMENT ADVISORS: BRANDON MICHAELS First Vice President Investments Director, National Retail Group Tel: (818) 212-2794

More information

VolitionRx Announces First Quarter 2016 Financial Results and Business Update

VolitionRx Announces First Quarter 2016 Financial Results and Business Update May 13, 2016 VolitionRx Announces First Quarter 2016 Financial Results and Business Update NAMUR, Belgium, May 13, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused

More information

MDCH IRB REVIEW APPLICATION Authority: Code of Federal Regulations Title 45 Part 46

MDCH IRB REVIEW APPLICATION Authority: Code of Federal Regulations Title 45 Part 46 The Michigan Department of Community Health Institutional Review Board for the Protection of Human Research Subjects Capitol View Building, 7 th Floor, 201 Townsend Street, Lansing, MI 48913 Phone: 517/241-1928

More information

PUBLIC SERVICE COMMISSION OF THE DISTRICT OF COLUMBIA 1325 G STREET N.W., SUITE 800 WASHINGTON, D.C ORDER

PUBLIC SERVICE COMMISSION OF THE DISTRICT OF COLUMBIA 1325 G STREET N.W., SUITE 800 WASHINGTON, D.C ORDER PUBLIC SERVICE COMMISSION OF THE DISTRICT OF COLUMBIA 1325 G STREET N.W., SUITE 800 WASHINGTON, D.C. 20005 ORDER June 24, 2016 FORMAL CASE NO. 1017, IN THE MATTER OF THE DEVELOPMENT AND DESIGNATION OF

More information

Corporate Presentation

Corporate Presentation Carriers Injectable to oral Progressive/Practical Innovation Emisphere Products Corporate Presentation November 2015 Patients OTCBB: EMIS Safe Harbor Statement The statements in this presentation or oral

More information

(City, State, Zip Code)

(City, State, Zip Code) This Partner Agency Agreement, dated this day of, 2015, is between COMMUNITY FOOD SHARE, INC. (CFS), whose address is 650 South Taylor Avenue, Louisville, CO 80027, and (Partner Agency) whose address is

More information

Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer

Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies

More information

J.D. Power and Associates Reports: Pharmacy Customers Have Higher Expectations for Short Wait Times

J.D. Power and Associates Reports: Pharmacy Customers Have Higher Expectations for Short Wait Times Reports: Pharmacy Customers Have Higher Expectations for Short Wait Times Good Neighbor Pharmacy, Health Mart, Kaiser Permanente Pharmacy, Publix and Target Rank Highest in Pharmacy Customer Satisfaction

More information

Liquid Biopsies. Next Generation Cancer Molecular Diagnostics

Liquid Biopsies. Next Generation Cancer Molecular Diagnostics Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology

More information

Galvus US NDA Approvable - Overview

Galvus US NDA Approvable - Overview Galvus US NDA Approvable - Overview Galvus NDA filed with FDA Jan 2006 PDUFA action date extended by 3 months until February 26th 2007 Significant new clinical data added to NDA - Approximately 1000 patient

More information

Jefferies Healthcare Conference. June 2016

Jefferies Healthcare Conference. June 2016 Jefferies Healthcare Conference June 2016 Today s Speakers John Figueroa Chief Executive Officer Vic Breed Chief Financial Officer Joined Genoa in July 2014 Previously served the dual roles of CEO of Apria

More information

Annual Meeting of Stockholders. June 25, 2008

Annual Meeting of Stockholders. June 25, 2008 Annual Meeting of Stockholders June 25, 2008 1 Forward-Looking and Cautionary Statement This is an oral presentation which is accompanied by slides. Investors are urged to review Rite Aid s SEC filings.

More information

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014 1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include

More information

Committed to Environment, Health, & Safety

Committed to Environment, Health, & Safety Committed to Environment, Health, & Safety Environment, Health, and Safety Management System and Policy of W. R. Grace & Co. November 8, 2018 The Grace Environment, Health, and Safety Management System,

More information

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE Case 199-mc-09999 Document 654 Filed 11/09/11 Page 1 of 12 PageID # 61421 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE NOVARTIS PHARMACEUTICALS CORPORATION, NOVARTIS AG, NOVARTIS PHARMA

More information

COMPANY PRESENTATION JULY Bob Bechard Executive Vice-President Corporate Development & Licensing

COMPANY PRESENTATION JULY Bob Bechard Executive Vice-President Corporate Development & Licensing COMPANY PRESENTATION JULY 2018 Bob Bechard Executive Vice-President Corporate Development & Licensing Forward Looking Statements Some statements in this release may contain forward-looking information.

More information

Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call

More information

Nexus BioPharma, Inc. Opportunity Overview

Nexus BioPharma, Inc. Opportunity Overview Nexus BioPharma, Inc Opportunity Overview Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange

More information

BERZACK. exclusive single tenant offering. 6% CAP - Walgreens. 410 Old Polk City Road Lakeland, FL WARREN BERZACK. Principal

BERZACK. exclusive single tenant offering. 6% CAP - Walgreens. 410 Old Polk City Road Lakeland, FL WARREN BERZACK. Principal exclusive single tenant offering 6% CAP - Walgreens Lee & Associates LA North/Ventura, Inc. Corporate ID #01191898 A Member of the Lee & Associates Group of Companies 15250 Ventura Blvd., Suite 100 Sherman

More information

Oragenics Shareholder Update

Oragenics Shareholder Update January 4, 2017 Oragenics Shareholder Update Advances Drug Development Programs Focused on Conditions with Significant Unmet Medical Needs TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE MKT:OGEN.BC),

More information

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,

More information

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated

More information